Something is going terribly wrong with the EU Compulsory Licensing Regulation
This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...
TRIPS, technology transfer and access to pandemic countermeasures: What the WHO Pandemic Treaty must...
The scrambling for access to Covid-19 vaccines by developing countries has reignited the debate on the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS)...
It is not too late to solve the know-how problem in the WHO Pandemic...
Introduction
One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...
What is the ‘know-how gap’ problem and how might it impact scaling up production...
This entire article is also available as a PDF by clicking here.
1. Introduction.
How relevant are concerns about intellectual property rights causing problems for...
Corbyn’s Compulsory Licenses. Will they work?
On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...
Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect...
The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
Medicines Excitement in the Netherlands – New Health Minister announces firm action on...
The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
The European Commission’s proposal for an EU wide compulsory licensing mechanism
In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...